Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
GLP-1 receptor agonists are emerging as a promising treatment for IIH, with early evidence that they may reduce intracranial pressure through weight loss and direct effects on CSF production
Receptor occupancy analysis demonstrates that 5 mg weekly tirzepatide engages the GLP-1R to a similar degree as 1 mg weekly semaglutide (47)
May your follicles stay active, your nutrients stay abundant, and your recovery stay steady.
In addition to acting through the p38 pathway, GLP-1RAs also promote the increase of PKA levels via the cAMP-dependent pathway, which in turn prevents the phosphorylation of epidermal growth factor receptor (EGFR) and activator of transcription 3 (STAT3), resulting in the inactivation of the EGFR-STAT3 signaling pathway in tumor cells and subsequently downregulating several downstream effector genes such as myelocytomatosis oncogene (c-Myc), survivin, cyclin D1, Bcl-xl, and Bcl-2, thereby inducing apoptosis in tumor cells in a dose-dependent manner [70, 73]
Benefits of GLP-1s Beyond Weight Loss: Addiction and Chemical Dependency Whats more, these drugs even have an impact on addictive behaviors
Research gaps and future directions for SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease SGLT2, sodium-glucose cotransporter 2
US$ 21.53
US$ 21.36
US$ 29.95
US$ 22.79
